Skip Navigation



QJM Advance Access published online on October 28, 2005
QJM, doi:10.1093/qjmed/hci136
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
98/12/845    most recent
hci136v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ohashi, R.
Right arrow Articles by Chen, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohashi, R.
Right arrow Articles by Chen, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Review

Reverse cholesterol transport and cholesterol efflux in atherosclerosis

R. Ohashi 1, H. Mu 1, X. Wang 1, Q. Yao 1, and C. Chen 1*

1 From the Molecular Surgeon Research Center, Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, USA

* To whom correspondence should be addressed.
C. Chen, E-mail: jchen{at}bcm.tmc.edu


  Abstract

Reverse cholesterol transport (RCT) is a pathway by which accumulated cholesterol is transported from the vessel wall to the liver for excretion, thus preventing atherosclerosis. Major constituents of RCT include acceptors such as high-density lipoprotein (HDL) and apolipoprotein A-I (apoA-I), and enzymes such as lecithin:cholesterol acyltransferase (LCAT), phospholipid transfer protein (PLTP), hepatic lipase (HL) and cholesterol ester transfer protein (CETP). A critical part of RCT is cholesterol efflux, in which accumulated cholesterol is removed from macrophages in the subintima of the vessel wall by ATP-binding membrane cassette transporter A1 (ABCA1) or by other mechanisms, including passive diffusion, scavenger receptor B1 (SR-B1), caveolins and sterol 27-hydroxylase, and collected by HDL and apoA-I. Esterified cholesterol in the HDL is then delivered to the liver for excretion. In patients with mutated ABCA1 genes, RCT and cholesterol efflux are impaired and atherosclerosis is increased. In studies with transgenic mice, disruption of ABCA1 genes can induce atherosclerosis. Levels of HDL are inversely correlated with incidences of cardiovascular disease. Supplementation with HDL or apoA-I can reverse atherosclerosis by accelerating RCT and cholesterol efflux. On the other hand, pro-inflammatory factors such as interferon-gamma (IFN-{gamma}), endotoxin, tumour necrosis factor-alpha (TNF-{alpha}) and interleukin-1 beta (IL-1{beta}), can be atherogenic by impairing RCT and cholesterol efflux, according to in vitro studies. RCT and cholesterol efflux play a major role in anti-atherogenesis, and modification of these processes may provide new therapeutic approaches to cardiovascular disease. Further research on new modifying factors for RCT and cholesterol efflux is warranted.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
U. Maitra, J. S. Parks, and L. Li
An Innate Immunity Signaling Process Suppresses Macrophage ABCA1 Expression through IRAK-1-Mediated Downregulation of Retinoic Acid Receptor {alpha} and NFATc2
Mol. Cell. Biol., November 15, 2009; 29(22): 5989 - 5997.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
T. Juan, M. M. Veniant, J. Helmering, P. Babij, D. M. Baker, M. A. Damore, M. B. Bass, T. Gyuris, M. Chhoa, C.-M. Li, et al.
Identification of three loci affecting HDL-cholesterol levels in a screen for chemically induced recessive mutations in mice
J. Lipid Res., March 1, 2009; 50(3): 534 - 545.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
M. S. Desai, M. M. Mariscalco, A. Tawil, J. G. Vallejo, and C. W. Smith
Atherogenic diet-induced hepatitis is partially dependent on murine TLR4
J. Leukoc. Biol., June 1, 2008; 83(6): 1336 - 1344.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
X. Wang, D. Liao, U. Bharadwaj, M. Li, Q. Yao, and C. Chen
C-Reactive Protein Inhibits Cholesterol Efflux From Human Macrophage-Derived Foam Cells
Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): 519 - 526.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M. Moerland, H. Samyn, T. van Gent, M. Jauhiainen, J. Metso, R. van Haperen, F. Grosveld, A. van Tol, and R. de Crom
Atherogenic, enlarged, and dysfunctional HDL in human PLTP/apoA-I double transgenic mice
J. Lipid Res., December 1, 2007; 48(12): 2622 - 2631.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
X. Wang, H. Mu, H. Chai, D. Liao, Q. Yao, and C. Chen
Human Immunodeficiency Virus Protease Inhibitor Ritonavir Inhibits Cholesterol Efflux from Human Macrophage-Derived Foam Cells
Am. J. Pathol., July 1, 2007; 171(1): 304 - 314.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Shimamura, M. Matsuda, H. Yasumo, M. Okazaki, K. Fujimoto, K. Kono, T. Shimizugawa, Y. Ando, R. Koishi, T. Kohama, et al.
Angiopoietin-Like Protein3 Regulates Plasma HDL Cholesterol Through Suppression of Endothelial Lipase
Arterioscler Thromb Vasc Biol, February 1, 2007; 27(2): 366 - 372.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.